COMPANY

Aqualung Therapeutics, Corp.

HQ: Juno Beach, FL source · aqualungtherapeutics.com ↗ · Southeast

Location: Juno Beach, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: pulmonary hypertension inflammatory bowel disease fibrosis Acute Respiratory Distress Syndrome Human ARDS chorioamnionitis ALT-100 mAb ALT-100

2Trials (company is sponsor)17NIH grants

Timeline

Sep 17, 2025 Grant Government grant — STTR: $284,699 (annual award, as published), announced Sep 17, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
Dec 1, 2023 Trial start Phase 2: Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS source ↗
Jul 5, 2022 Trial start Phase 1: First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100 source ↗

Upcoming milestones

May 1, 2027 (ESTIMATED) · Phase 2 · Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS · NCT05938036

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 17, 2025 Government grant — STTR: $284,699 (annual award, as published), announced Sep 17, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05938036	Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS	Phase 2	Active, not recruiting	Dec 1, 2023	May 1, 2027 (estimated)
NCT05426746	First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100	Phase 1	Completed	Jul 5, 2022	May 18, 2023 (actual)

NIH awards 17

Annual award amounts. Total $11.3M.

Sep 11, 2024 NIH award 5R44HL145930-05 FY2024: $957,594 awarded for that fiscal year; activity R44 (SBIR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. A Randomized Phase 2A Clinical Tr source ↗
Jul 31, 2024 NIH award 5R42HL164300-03 FY2024: $808,999 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Preclinical Development of a Nove source ↗
Jul 16, 2024 NIH award 5R42DK135208-03 FY2024: $975,215 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Targeting the eNAMPT/TLR4 pathway source ↗
Sep 19, 2023 NIH award 4R42HL164300-02 FY2023: $809,000 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Preclinical Development of a Nove source ↗
Sep 8, 2023 NIH award 2R44HL145930-04 FY2023: $1,500,000 awarded for that fiscal year; activity R44 (SBIR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. A Randomized Phase 2A Clinical source ↗
Aug 15, 2023 NIH award 4R42DK135208-02 FY2023: $975,215 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Targeting the eNAMPT/TLR4 pathway source ↗
Sep 22, 2022 NIH award 1R41HL164154-01 FY2022: $259,613 awarded for that fiscal year; activity R41 (STTR); PI MIELE, STANLEY; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Targeting the P Selectin Pathway to source ↗
Sep 19, 2022 NIH award 1R42DK135208-01 FY2022: $269,233 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Targeting the eNAMPT/TLR4 pathway source ↗
Aug 29, 2022 NIH award 1R42HL164300-01 FY2022: $259,613 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Preclinical Development of a Nove source ↗
May 30, 2022 NIH award 5R42HL152888-03 FY2022: $1,000,000 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. eNamptorTM: A Humanized mAb To source ↗
Jun 1, 2021 NIH award 4R42HL152888-02 FY2021: $1,000,000 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. eNamptorTM: A Humanized mAb To source ↗
Apr 23, 2021 NIH award 5R42HL145930-03 FY2021: $750,000 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Novel Therapeutic Antibody Target source ↗
Sep 18, 2020 NIH award 1R41HD101202-01A1 FY2020: $265,096 awarded for that fiscal year; activity R41 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Extracellular NAMPT is a Novel source ↗
May 27, 2020 NIH award 1R42HL152888-01 FY2020: $300,001 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. eNamptorTM: A Humanized mAb To Re source ↗
May 12, 2020 NIH award 4R42HL145930-02 FY2020: $750,000 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Novel Therapeutic Antibody Target source ↗
Aug 8, 2019 NIH award 1R41HL147769-01 FY2019: $225,000 awarded for that fiscal year; activity R41 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. The CRIT-ICU Biomarker Panel for source ↗
May 25, 2019 NIH award 1R42HL145930-01 FY2019: $225,000 awarded for that fiscal year; activity R42 (STTR); PI GARCIA, JOE G. N.; recipient as written: AQUALUNG THERAPEUTICS CORP., Juno Beach, FL. Novel Therapeutic Antibody Target source ↗